| 000 | 00916nam a2200253 4500 | ||
|---|---|---|---|
| 003 | KMLcat | ||
| 008 | 160317b xxu||||| |||| 00| 0 eng d | ||
| 020 | _a9290222883 | ||
| 041 | _aEng | ||
| 082 |
_a616.9792 _bANT |
||
| 245 |
_aAntiretrovirals for HIV _ba compilation of facts and product information |
||
| 260 |
_c2006 _aNew Delhi _bWHO-SEARO _g2006 |
||
| 300 |
_a115 p. _bill. _c21 cm. |
||
| 650 | _aACQUIRED IMMUNODEFICIENCY SYNDROME | ||
| 655 |
_aAcquired Immunodeficiency Syndrome - drug therapy _914445 |
||
| 655 |
_aAntiretroviral therapy, highly active - adverse effects _914446 |
||
| 655 |
_aHIV infections - drug therapy _98269 |
||
| 655 |
_aDrug resistance, viral _914447 |
||
| 655 |
_aNucleoside - triphosphatase _914448 |
||
| 655 |
_aPrescriptions, drug - methods _914449 |
||
| 655 |
_aProtease inhibitors _910780 |
||
| 856 | _uhttp://apps.who.int/iris/handle/10665/204781 | ||
| 942 |
_cSPR _2ddc |
||
| 999 |
_c4691 _d4691 |
||